Funding
- DFG Research Training Grant (GRK2504) „Novel antiviral strategies: from small molecules to immune intervention“.
- Bill & Melinda Gates Foundation, Collaboration on AIDS Vaccine Discovery (CAVD) (OPP1040727) „Induction of affinity-matured HIV Env antibodies in the absence of HIV specific T helper cells".
- EU, European AIDS vaccine initiative 2020 (EAVI 2020).
- DFG UE 45/23-1 „Effector mechanisms of neutralizing and non-neutralizing antibodies against SARS-CoV-2 in a small animal model“.
- DFG UE 45/21-1 „Multifunctional calciumphosphat nanoparticles as novel vaccine platform against HIV-1“.
- DFG UE 45/13-2 „Relevance of Fc effector functions for protection from infection of the first cells in an HIV-1 non-human primate model“.
- BMBF (01KI2043A) „Human antibodies to SARS-Cov2 for the prophylaxis and therapy of COVID-19 (CoVER Ab)“.
- STMWK „Bayerisches Zentrum für präventive Infektionsmedizin“
- BMBF „COVIM – Collaborative Immunity Platform of the NUM (COVIM)“.
- Bayerische Forschungsstiftung „Long-term protection by SARS-CoV-2 antibodies“.
Bayerische Forschungsstiftung „DeeP‐CMV: Diagnostic, therapy & prevention of CMV‐infection“.
Collaborations
- Prof. Dr. Dennis Burton, The Scripps Research Institute, La Jolla, USA
- Prof. Dr. Jutta Eichler, Professor of Medicinal Chemistry, Department of Chemistry and Pharmacy, Faculty of Sciences, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Germany
- Prof. Dr. Matthias Epple, Institute of Inorganic Chemistry, Essen, Germany
- Prof. Dr. Olaf Gefeller, Chair of Medical Biometry and Epidemiology, Institute of Medical Informatics, Biometry and Epidemiology, Faculty of Medicine, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Germany
- Prof. Dr. Dirk Grimm, Viral Vector Technologies, University Hospital Heidelberg, Germany
- PD Dr. Thomas Grunwald, Preclinical Validation Unit, Fraunhofer-Institute for Cell Therapy and Immunology, Leipzig, Germany
- Prof Dr. Holger Hackstein, Department of Transfusion Medicine and Haemostaseology, Uniklinikum Erlangen, Germany
- Prof. Dr. Thomas Harrer, Department of Medicine 3 – Rheumatology and Immunology, Uniklinikum Erlangen, Germany
- Prof. Dr. Hans-Martin Jäck, Division of Immunology, Department of Medicine 3 - Rheumatology and Immunology, Uniklinikum Erlangen, Germany
- Prof. Dr. Florian Klein, Institute of Virology, University Hospital of Cologne, Germany
- Prof. Dr. Johannes G. Liese, Department of Pediatrics, Uniklinikum Würzburg, Germany
- Prof. Dr. Anja Lux, Professorship for Integrated Immunology, Chair of Genetics, Faculty of Sciences, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Germany
- Prof. Dr. Ulla Protzer, Institute of Virology, Technical University of Munich, Germany
- Dr. Christiane Stahl-Hennig, Unit of Infection Models at the German Primate Center, Göttingen, Germany
- Prof. Dr. Heinrich Sticht, Professorship for Bioinformatics, Institute for Biochemistry, Faculty of Medicine, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Germany
- Prof. Dr. Ralf Wagner, Institute for Microbiology and Hygiene, Universitätsklinikum Regensburg, Germany
- Prof. Dr. Thomas Winkler, Professorship for Genetics, Faculty of Sciences, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Germany
- Prof. Rich Wyatt, The Scripps Research Institute, La Jolla, USA
